D. Ryan Cook

Induction and maintenance characteristics of anesthesia with desflurane and nitrous oxide in infants and children.

To determine the induction and maintenance characteristics of desflurane in pediatric patients, the authors anesthetized 206 infants and children aged 1 month to 12 yr with nitrous oxide plus desflurane and/or halothane in oxygen. Patients were assigned to one of four groups: anesthesia was 1) induced and maintained with desflurane after premedication with an oral combination of meperidine, diazepam, and atropine; 2) induced and maintained with desflurane; 3) induced with halothane and maintained with desflurane; or 4) induced and maintained with halothane. An unblinded observer recorded time to loss of consciousness (lid reflex), time to intubation, and clinical characteristics of the induction and maintenance of anesthesia. Moderate-to-severe laryngospasm (49%) and moderate-to-severe coughing (58%) occurred frequently during induction of anesthesia with desflurane; the incidence of these was not altered by premedication. In contrast, laryngospasm and coughing were rare during induction of anesthesia with halothane. In unpremedicated patients, time to loss of lid reflex (mean +/- SD) was similar for desflurane (2.4 +/- 1.2 min) and halothane (2.1 +/- 0.8 min). During induction of anesthesia, before laryngoscopy and intubation, mean arterial pressure less than 80% of baseline was more common with halothane; heart rate and mean arterial pressure greater than 120% of baseline were more common with desflurane. Intraoperatively, heart rate greater than 120% of baseline was more common with desflurane; blood pressures were similar for the two anesthetics. The authors conclude that the high incidence of airway complications during induction of anesthesia with desflurane limits its utility for inhalation induction in pediatric patients. Anesthesia can be safely maintained with desflurane if induced with a different anesthetic.

In Vitro Metabolism of Mivacurium Chloride (bw B1090u) and Succinylcholine

The in vitro rates of metabolism of mivacurium chloride and succinylcholine in pooled human plasma were compared. In addition, the rate of metabolism of mivacurium in buffered solutions of butyrylcholinesterase (E.C. 3.1.1.8) and acetylcholinesterase (E.C. 3.1.1.7) was determined. Succinylcholine concentrations were measured spectrophoto-metrically, and mivacurium concentrations were determined with a high-pressure liquid chromatographic assay. The hydrolysis of mivacurium in plasma followed first-order kinetics, and the rate of hydrolysis decreased as plasma was serially diluted. The Michaelis-Menten constant (Km) for mivacurium metabolism in plasma was 245/μmol/L, and the maximum velocity (Vmax) was 50 U/L; the Km for succinylcholine was 37 μmol/L, and Vmax was 74 U/L. At comparable multiples of the Km the hydrolysis rate of mivacurium was 70% of that of succinylcholine. Mivacurium was metabolized significantly in solutions containing butyrylcholinesterase, but only minimally in solutions containing acetylcholinesterase.

Effects of Bolus Administration of ORG-9426 in Children during Nitrous Oxide–Halothane Anesthesia

ORG-9426 is a new steroidal nondepolarizing neuromuscular blocking drug. We determined the dose-response relationship of ORG-9426 in 62 children (aged 1-5 yr) during nitrous oxide-halothane anesthesia by means of log-probit transformation and least-squares linear regression of the initial dose and response. Twelve additional patients received a bolus of 600 micrograms/kg (2 X the dose estimated to produce 95% depression of neuromuscular function [ED95]) of ORG-9426. Neuromuscular blockade was monitored by recording the electromyographic activity of the adductor pollicis muscle resulting from supramaximal stimulation of the ulnar nerve at 2 Hz for 2 s at 10-s intervals. To determine the dose-response relationship, patients randomly received initial bolus doses of 120 (n = 15), 160 (n = 16), 200 (n = 16), or 240 (n = 15) micrograms/kg ORG-9426. The resulting dose estimated to produce 50% depression of neuromuscular function (ED50) and ED95 were 179 and 303 micrograms/kg, respectively. Time from administration of 600 micrograms/kg to onset of 90% and 100% neuromuscular block was 0.8 +/- 0.1 (0.5-1.3) and 1.3 +/- 0.2 (0.7-2.8) min. The time to recovery of neuromuscular transmission to 25% (T25) was 26.7 +/- 1.9 (17.2-39.0) min. The recovery index (T25-75) was 11.0 +/- 1.6 (6.0-22.8) min, and the time to complete recovery of the magnitude of the fourth response to a train-of-four stimuli divided by the magnitude of the first response (T4/T1) greater than or equal to 0.75 was 41.9 +/- 3.2 (26.5-57.7) min.(ABSTRACT TRUNCATED AT 250 WORDS)

Clinical Pharmacokinetics of the Newer Intravenous Anaesthetic Agents

SummaryIn the last 15 years the role of opioids in anaesthesia management has undergone dramatic change. Initially used as premedicants, or adjuvants to inhalation anaesthetic agents or as analgesics for postoperative pain relief narcotics have now evolved into primary anaesthetic agents, primarily because of their ability to maintain cardiovascular stability especially in patients with compromised myocardial function. Sufentanil, alfentanil, and lofentanil are 3 new synthetic congeners of fentanyl. Sufentanil and alfentanil afford not only the haemodynamic stability but also the desirable anaesthetic properties of analgesia, and unconsciousness. Their major advantage lies in their pharmacokinetic behaviour; a rapid onset of action and short elimination half-life, allowing for greater flexibility in anaesthetic management. Sufentanil’s pharmacokinetic profile is consistent with a 2-compartment model. Its elimination half-life is 149 minutes and its clearance is 11.3 ml/min/kg. Alfentanil’s pharmacokinetic profile has been described by both 2- and 3-compartment models. Its distribution and redistribution are rapid, with an elimination half-life of 83 to 137 minutes and a clearance of 4.37 to 6.47 ml/min/kg in adult patients. Lofentanil, however, is an extremely long-acting narcotic analgesic. Presently, its use is justified only when prolonged mechanical ventilation is anticipated.Etomidate, a carboxylated imidazole, is rapidly distributed within a central compartment and then to peripheral compartments; its slow distribution and terminal elimination half-lives are 28 and 273 to 330 minutes, respectively, and its clearance (11.6 to 25 ml/min/kg) is equal to its hepatic plasma flow. Its ability to maintain cardiovascular stability in patients with compromised myocardial function make it a useful induction agent. However, reports of increed mortality and inhibition of steroidogenesis in patients receiving either single injections or constant infusions have created controversies regarding its use.Minaxolone is a water-soluble steroid whose pharmacokinetic profile is consistent with a 2-compartment model. Distribution is rapid with a mean half-life of 2.1 minutes and an elimination half-life of 47 minutes. There do not appear to be any cumulative effects. Plasma levels on recovery were similar in those patients receiving single bolus or continuous infusions.Midazolam and flunitrazepam are two new benzodiazepines. As a class of drugs, benzodiazepines provide the pharmacological properties of anxiolysis, sedation, hypnosis, muscle relaxation, amnesia and anticonvulsant activity. It appears that their sedative hypnotic effect is related to their ability to occupy benzodiazepine receptors in the brain. Onset of action is related to the ability to penetrate the blood-brain barrier. Those drugs with rapid onset penetrate quickly, while those drugs with slower onset appear in the cerebrospinal fluid later. After a single intravenous injection, onset and duration of action are determinedby redistribution; whereas after repeated injections the determinants of action are governed by clearance and elimination half-life.Midazolam’s pH-dependent ring phenomena create a water soluble, rapid-acting drug with a short duration of action. Age, gender and obesity can alter its pharmacokinetics.Flunitrazepam is insoluble in water and is characterised by a slow onset, prolonged recovery time and marked individual variability. Its pharmacokinetic profile has been described by both 2- and 3-compartment open models.Disoprofol (propofol) is an isopropylphenol whose pharmacokinetic profile is best described by a 2-compartment open model with a distribution half-life of 2.5 minutes and an elimination half-life of 54 5 minutes. The waking concentration is independent of doses administered, and intravenous infusions are not associated with alteration in liver function.

Anaesthetic management of infants with glycogen storage disease type II: a physiological approach.

Pompe or Glycogen Storage Disease type II (GSD‐II) is a genetic disorder affecting both cardiac and skeletal muscle. Historically, patients with the infantile form usually die within the first year of life due to cardiac and respiratory failure. Recently a promising enzyme replacement therapy has resulted in improved clinical outcomes and a resurgence of elective anaesthesia for these patients. Understanding the unique cardiac physiology in patients with GSD‐II is essential to providing safe general anaesthesia.

Neuromuscular effects of 600 μg·kg−1 of rocuronium in infants during nitrous oxide‐halothane anaesthesia

Rocuronium bromide (Zemuron) is a new steroidal nondepolarizing neuromuscular blocking drug. We were interested in determining the effect of a bolus of rocuronium in infants during halothane anaesthesia as we did previously in older children. Eighteen infants (2‐11 months) received a bolus of 600 μg·kg−1, which is equal to twice the dose of rocuronium estimated to produce 95% depression of neuromuscular function (ED95) in children (2‐12 yr). Neuromuscular blockade was monitored by recording the electromyographic activity of the adductor pollicis muscle resulting from supramaximal stimulation of the ulnar nerve at 2 Hz for 2 s at 10‐s intervals. Time (mean ± SEM, range) from administration of 600 μg·kg−1 rocuronium to 90% (B90) and 100% (B100) neuromuscular block was 37 ± 2 (20‐60) s and 64 ± 10 (20‐180) s, respectively. The time to recovery of neuromuscular transmission to 10% (T10) was 35.3 ± 3.0 (20.7‐57.8) min and to 25% of baseline (T25) was 41.9 ± 3.2 (24.3‐67.7) min. The recovery index (T25‐T75) was 26.6 ± 2.7 (11.7‐44.5) min, and the time to recovery of the train‐of‐four ratio (T4/T1) ± 0.75 was 82.1 ± 6.9 (53.2‐138.3) min. The plasma concentration of rocuronium when T1 had recovered to about 30% was 654 ± 34 (417‐852) ng·ml−1 which is similar to that observed in children. Six‐hundred μg·kg−1 of rocuronium has a rapid onset of effect in infants and prolonged duration of action in infants compared to children.

Hemodynamic effects of isoflurane in the newborn piglet: comparison with halothane

: To better understand the mechanism of hypotension and bradycardia that may occur in newborn infants during isoflurane anesthesia, we studied the hemodynamic changes in the major determinants of cardiac output in 15 newborn piglets given 0.5, 1.0, and 1.3 minimal alveolar concentrations (MAC) of isoflurane and in nine sham-instrumented, age-matched control animals. Cardiac output did not differ from the baseline reading or the control group at any isoflurane dose. Mean aortic pressure (MAP) decreased 23-45% in a dose-related manner. Total peripheral resistance index (TPRI) decreased 29% at 0.5 MAC, but did not decline further at higher concentrations. Because the decrease in MAP was offset by a similar reduction in TPRI, cardiac output did not change. Heart rate decreased significantly at 1.3 MAC (-19%). Contractility was depressed at all concentrations: left ventricular dP/dT decreased progressively at 0.5 and 1.0 MAC, and echocardiographic shortening fraction decreased significantly at 1.0 MAC. Left ventricular end-diastolic pressure was not affected. Eight of twelve animals who had bradycardia while breathing isoflurane were atrially paced at their baseline heart rate. Because pacing did not restore MAP, TPRI, and LV dP/dT/DP40 (a contractile index independent of preload and afterload) to control values, bradycardia was not primarily responsible for depression of these variables. At equipotent concentrations, isoflurane reduced MAP and TPRI more than, and cardiac output less than, halothane did in previous studies in this laboratory. Heart rate and dP/dT were decreased to a similar extent by both agents. Blood, heart, and brainstem isoflurane LD:MAC ratios were 2.04, 2.00, and 2.84, respectively, indicating a relatively low margin of safety for isoflurane in young piglets.

Comparison of cisatracurium and vecuronium by infusion in neonates and small infants after congenital heart surgery.

Background:Neonates and infants often require extended periods of mechanical ventilation facilitated by sedation and neuromuscular blockade. Methods:Twenty-three patients aged younger than 2 yr were randomly assigned to receive either cisatracurium or vecuronium infusions postoperatively in a double-blinded fashion after undergoing congenital heart surgery. The infusion was titrated to maintain one twitch of a train-of-four. The times to full spontaneous recovery of train-of-four without fade, extubation, intensive care unit discharge, and hospital discharge were documented after drug discontinuation. Sparse sampling after termination of the infusion and a one-compartment model were used for pharmacokinetic analysis. The Mann-Whitney U test and Student t test were used to compare data between groups. Results:There were no significant differences between groups with respect to demographic data or duration of postoperative neuromuscular blockade infusion. The median recovery time for train-of-four for cisatracurium (30 min) was less than that for vecuronium (180 min) (P < 0.05). Three patients in the vecuronium group had prolonged train-of-four recovery: Two had long elimination half-lives for vecuronium, and one had a high concentration of 3-OH vecuronium. There were no differences in extubation times, intensive care unit stays, or hospital stays between groups. Conclusions:Our results parallel data from adults demonstrating a markedly shorter recovery of neuromuscular transmission after cisatracurium compared with vecuronium. Decreased clearance of vecuronium and the accumulation of 3-OH vecuronium may contribute to prolonged spontaneous recovery times. Cisatracurium is associated with faster spontaneous recovery of neuromuscular function compared with vecuronium but not with any differences in intermediate outcome measures in neonates and infants.

Pharmacokinetics of Sufentanil in Adolescent Patients Renal Failure

The role of the kidney in sufentanil elimination or metabolism has not been defined. The effects of chronic renal failure (CRF) on the pharmacokinetic profile of sufentanil were evaluated in six adolescent patients undergoing renal transplantation, and these findings were compared with data from age-matched control patients with normal renal function who were undergoing other surgical procedures. Patients with CRF weighed significantly less than did the control patients (28.7 ± 5.7 vs 44.7 ± 12.9 kg [mean ± SD]). Although there was no statistical difference in the rate of clearance orapparent volume of distribution and half-life between the two groups, clearance and half-life were more variable among patients with CRF. In these patients, therefore, sufentanil dose must be carefully administered based on responses elicited in individual patients.

Mivacurium infusion during nitrous oxide—Isoflurane anesthesia: A comparison with nitrous oxide-opioid anesthesia

STUDY OBJECTIVE To determine the potentiation of the neuromuscular blockade induced by a titrated infusion of mivacurium in the presence of isoflurane versus a nitrous oxide (N2O)-opioid anesthesia. DESIGN An open-label, controlled study. SETTING The inpatient anesthesia service of two university medical centers. PATIENTS Thirty adults divided into two groups. INTERVENTION An intravenous infusion of mivacurium during anesthesia with N2O-opioid or N2O-isoflurane. MEASUREMENTS AND MAIN RESULTS A neuromuscular blockade was monitored by recording the electromyographic activity of the adductor pollicis muscle resulting from supramaximal stimulation at the ulnar nerve at 2 Hz for 2 seconds at 10-second intervals. The mivacurium infusion rate was significantly less in the presence of isoflurane [4.0 +/- 0.8 micrograms/kg/min (mean +/- SEM)] than during N2O-opioid anesthesia (6.4 +/- 0.6 micrograms/kg/min). The recovery rates did not differ between anesthetic groups. After the termination of the infusion, spontaneous recovery to T4/T1 of at least 0.75 occurred in an average of 17.9 +/- 1.5 minutes, with a mean recovery index (T25-75) of 6.0 +/- 0.7 minutes. CONCLUSION Isoflurane anesthesia reduces the infusion rate of mivacurium required to produce about 95% depression of neuromuscular function.